## **OPTIMA HEALTH COMMUNITY CARE**

## PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST\*

Directions: <u>The prescribing physician must sign and clearly print name</u> (<u>preprinted stamps not valid</u>) on this request. All other information may be filled in by office staff; fax to <u>1-800-319-5003</u>. No additional phone calls will be necessary if all information (<u>including phone and fax #s</u>) on this form is correct. Incomplete forms will delay the authorization process.

**<u>Drug Requested</u>**: **Ninlaro**® (ixazomib)

REVISED/UPDATED: 12/23/2017

DRUG INFORMATION: Complete information below. If incomplete, authorization process will be delayed.		
Drug Form/Strength/Quantity per Day:		
Dosing Schedule:	Length of Therapy:	
Diagnosis:	ICD Code, if applicable: _	
CLINICAL CRITERIA: To receive a SIX (6) month app checked to qualify or authorization process will be delayed	·	es below <u>must</u> be
Does member meet the following criteria?		
• Is prescriber an oncologist?		☐ Yes ☐ No
• Is member 18 years of age or older?		☐ Yes ☐ No
• Has member received at <u>one (1)</u> prior treatment for diag	nosis?	☐ Yes ☐ No
If YES, provide name of treatment regimen and dates of	of therapy below:	☐ Yes ☐ No
Treatment	Date received:	
Treatment	Date received:	
Treatment	Date received:	
• Will member be receiving both lenalidomide (Revlimide	®) and dexamethasone?	☐ Yes ☐ No
• Has prior authorization request for lenalidomide (Revlir	nid®) been completed and approved?	☐ Yes ☐ No
• Will strong CYP3A inducers (i.e., rifampin, phenytoin,	carbamazepine, St John's Wort) be admini	stered concurrently?
		☐ Yes ☐ No
• Is member receiving concurrent therapy with another pr <i>Examples include</i> : bortezomib (Velcade®), cafilzomib		☐ Yes ☐ No
** <u>Use of samples to initiate therapy does</u> * <u>Previous therapies will be verified through</u>		
Patient Name:		
Member Optima #:	Date of Birth:	
Prescriber Name:		
Prescriber Signature:		
Office Contact Name:		
Phone Number:		
DEA OR NPI #•		